The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | How treatment affects the development of secondary malignancies in patients with CLL
Thomas Chatzikonstantinou, MD, Center for Research and Technology Hellas, Thessaloniki, Greece, discusses secondary malignancies that are associated with chronic lymphocytic leukemia (CLL), emphasizing that these malignancies can negatively impact survival. He highlights the need for further research on how targeted therapies influence the development of secondary cancers, including myelodysplastic syndromes and skin cancers. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
